Predictors of Single-gland Vs Multigland Parathyroid Disease in Primary Hyperparathyroidism: a Simple and Accurate Scoring Model
Overview
Affiliations
Hypothesis: Preoperative clinical, biochemical, and imaging studies could be used to reliably select patients with single-gland primary hyperparathyroidism who could undergo minimally invasive parathyroidectomy and to determine whether additional perioperative testing is necessary.
Design: Retrospective analysis.
Setting: Tertiary referral center.
Patients: A total of 238 patients who underwent neck surgical exploration and parathyroidectomy for primary hyperparathyroidism from January 7, 2002, to December 23, 2004.
Main Outcome Measures: Demographic, clinical, biochemical, and imaging factors that predict single-gland vs multigland parathyroid disease, and biochemical cure.
Results: Of the 238 patients, 75.2% had a single adenoma, 21.4% had asymmetric 4-gland hyperplasia, and 3.4% had double adenomas. A biochemical cure was achieved in 99.2% of the patients. Preoperative calcium and intact parathyroid hormone levels were significantly higher (P = .03 and .04, respectively) and ultrasound and sestamibi scan results were more likely to be positive (both P<.001) in single-gland primary hyperparathyroidism. A dichotomous scoring model based on preoperative total calcium level (>/=3 mmol/L [>/=12 mg/dL]), intact parathyroid hormone level (>/=2 times the upper limit of normal levels), positive ultrasound and sestamibi scan results for 1 enlarged gland, and concordant ultrasound and sestamibi scan findings reliably distinguished single-gland vs multigland cases (P<.001). The positive predictive value of this scoring model to correctly predict single-gland disease was 100% for a total score of 3 or higher.
Conclusions: Preoperative biochemical and imaging study results reliably distinguished single-gland vs multigland parathyroid disease in primary hyperparathyroidism. Our findings suggest that patients with a score of 3 or higher can undergo a minimally invasive parathyroidectomy without the routine use of intraoperative parathyroid hormone or additional imaging studies, and those with a score of less than 3 should have additional testing to ensure that multigland disease is not overlooked.
Predicting Tumor Volume in Primary Hyperparathyroidism From Preoperative Clinical Data.
Nakai T, Horiuchi K, Okamoto T J Clin Endocrinol Metab. 2024; 110(2):e391-e396.
PMID: 38525667 PMC: 11747749. DOI: 10.1210/clinem/dgae185.
Primary hyperparathyroidism: predictors of sporadic multi-gland disease.
Yang L, Jing X, Pang H, Guan L, Li M Endocr Connect. 2024; 13(5).
PMID: 38513354 PMC: 11046330. DOI: 10.1530/EC-23-0492.
Laforgia R, Tomasicchio G, Cavalera F, Sblendorio M, Spadone A, Anelli F Front Endocrinol (Lausanne). 2023; 14:1278178.
PMID: 38027123 PMC: 10656609. DOI: 10.3389/fendo.2023.1278178.
Lawrence E, Johri G, Dave R, Li R, Gandhi A Langenbecks Arch Surg. 2023; 408(1):389.
PMID: 37806985 PMC: 10560634. DOI: 10.1007/s00423-023-03087-w.
Mohan Kumar R, Pannu A, Metcalfe E, Senbeto M, Balasubramanian S Front Endocrinol (Lausanne). 2023; 14:1198894.
PMID: 37693360 PMC: 10486897. DOI: 10.3389/fendo.2023.1198894.